IMR Press / EJGO / Volume 43 / Issue 2 / DOI: 10.31083/j.ejgo4302043
Open Access Case Report
CRS and HIPEC in a patient with recurrent ovarian cancer after PDS and adjuvant chemotherapy, a case report and MDT discussion
Show Less
1 Department of Gynecological Oncology, Metaxa Memorial Cancer Hospital, 18537 Piraeus, Greece
*Correspondence: (Alexandros Fotiou)
Academic Editor: Enrique Hernandez
Eur. J. Gynaecol. Oncol. 2022, 43(2), 368–371;
Submitted: 17 March 2021 | Revised: 29 March 2021 | Accepted: 12 April 2021 | Published: 15 April 2022
(This article belongs to the Special Issue Hyperthermic Intraperitoneal Chemotherapy to Gynaecological Oncology)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: Ovarian cancer is the most lethal gynecologic malignancy worldwide and is plagued by a high recurrence rate. Cytoreductive surgery and adjuvant chemotherapy are considered the gold standard treatment for advanced ovarian cancer patients. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a relatively new option, especially for patients with peritoneal and recurrent disease. Case: We intend to present a case of a patient with recurrent ovarian cancer managed initially with primary debulking surgery plus adjuvant chemotherapy and afterward with secondary cytoreduction and HIPEC. Conclusion: Complete cytoreduction remains the ultimate goal in the surgical treatment of patients with advanced stage ovarian cancer. Moreover, patients would benefit from the use of HIPEC after the optimal cytoreduction, especially in those with peritoneal metastases. Several studies have shown the utility of HIPEC regarding disease-free and overall survival after extended debulking surgery.

Cytoreductive surgery
Recurrent ovarian cancer
Back to top